Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKETprogram and two additional targets, with €25 million payment Encouraging preliminary TELLOMAK Phase
Monalizumab and IPH5201 developed in collaboration with AstraZeneca advanced into Phase 3 and 2 clinical trials in lung cancer, triggering $55M in milestone payments Second preclinical asset